IQ EQ FUND MANAGEMENT IRELAND Ltd Has $2.22 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Key Points

• IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in CRISPR Therapeutics by 79.8%, owning 65,195 shares worth $2.22 million after acquiring an additional 28,931 shares in the first quarter.
• Multiple hedge funds have been active around CRISPR shares, with institutional investors now collectively owning 69.20% of the company following significant increases from firms like NBC Securities and US Bancorp.
• Analysts have mixed opinions on CRISPR Therapeutics, with price targets ranging from $42.00 to $105.00 and a consensus rating of "Hold" reflecting the uncertainty surrounding the stock's future performance.

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 79.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,195 shares of the company's stock after buying an additional 28,931 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd owned approximately 0.08% of CRISPR Therapeutics worth $2,219,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. ARK Investment Management LLC raised its stake in shares of CRISPR Therapeutics by 13.3% during the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock worth $345,929,000 after acquiring an additional 1,192,336 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. Capital International Investors increased its stake in CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after purchasing an additional 816,789 shares in the last quarter. Baker BROS. Advisors LP increased its stake in CRISPR Therapeutics by 55.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after purchasing an additional 464,936 shares in the last quarter. Finally, Norges Bank acquired a new position in CRISPR Therapeutics during the 4th quarter valued at approximately $17,458,000. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Stock Up 1.3%

Shares of NASDAQ CRSP traded up $0.75 during midday trading on Wednesday, hitting $56.34. The stock had a trading volume of 2,429,529 shares, compared to its average volume of 3,921,809. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $71.13. The company has a fifty day moving average price of $50.45 and a 200 day moving average price of $43.63. The company has a market capitalization of $4.87 billion, a price-to-earnings ratio of -10.38 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.29) EPS for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm's revenue was up 72.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.49) earnings per share. On average, research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insiders Place Their Bets

In related news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the sale, the insider directly owned 6,068 shares in the company, valued at $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Simeon George acquired 989,812 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The shares were bought at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the purchase, the director owned 1,730,179 shares of the company's stock, valued at approximately $90,021,213.37. This represents a 133.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

CRSP has been the topic of a number of recent analyst reports. Piper Sandler restated an "overweight" rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a report on Friday, May 16th. JMP Securities reiterated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Chardan Capital restated a "buy" rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday. Finally, Bank of America cut their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $70.60.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.